BriaCell Therapeutics Corp.
BCTXL
NASDAQ1.15
USD
-0.05
- -
CIK
0001610820
ISIN
CA1079301257
CUSIP
107930125
Return %
Stock
S&P500
1Y
20.92
15.01
3Y
20.92
82.56
5Y
20.92
79.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- William V. Williams
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Bellevue Centre West Vancouver BC Canada V7T 2X1
- IPO Date
- Jan 14, 2026
- CIK
- 0001610820
- Website
- briacell.com
- Similar Companies
- Business
- BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing targeted cell-based immunotherapies for cancer, with headquarters in Philadelphia, Pennsylvania, and Vancouver, British Columbia; it was founded in 2006. The company’s lead product candidate is Bria-IMT™, an off-the-shelf, patented cell-based immunotherapy being advanced in a pivotal Phase 3 study for metastatic breast cancer in combination with an immune checkpoint inhibitor; BriaCell also develops Bria-OTS™ and Bria-OTS+™, next-generation personalized off-the-shelf immunotherapy platforms being studied for breast cancer, prostate cancer, lung cancer, melanoma, and other cancers, including Bria-BRES™ and Bria-PROS+ programs. BriaCell operates in the biotechnology and cancer therapeutics segment and targets patients with advanced or hard-to-treat malignancies through clinical development, including HLA-matched personalized immunotherapy approaches and companion-oriented platform technologies. Recent corporate and operational developments include FDA clearance to initiate a Bria-PROS+ prostate cancer clinical study, expansion of the pivotal Bria-IMT Phase 3 metastatic breast cancer study to Memorial Sloan Kettering Cancer Center, continued positive Data Safety Monitoring Board recommendations for the Phase 3 study, a strategic manufacturing arrangement with FUJIFILM Biotechnologies to support Bria-IMT supply, and a partnership with Uneedle for intradermal microneedle administration of Bria-IMT. The company also reported positive 2026 clinical data presentations at ASCO, including survival and biomarker findings supporting its lead program, while advancing broader development of its off-the-shelf immunotherapy pipeline.